Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors Hematology
Biosimilars
Global Health
Abbreviations
KisqaliⓇ - CDK4/6 inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03701334 NATALEE (CLEE011012301C)
Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast
cancer (EBC)
Phase 3
5101
Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions
for Efficacy End Points in adjuvant breast cancer trials)
Ribociclib endocrine therapy
Endocrine therapy
Pre and postmenopausal women and men with HR-positive, HER2-negative EBC,
after adequate surgical resection, who are eligible for adjuvant endocrine therapy
Target Patients
Read-out Milestone(s)
2022
Publication
TBD
120 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation